

### เอกสารอ้างอิง

อัจฉริยะ ไศลະสูต 2006 (2549) เซลล์วิทยาวินิจฉัย ใน พยาธิวิทยาคลินิกทางสัตวแพทย์ ห้า  
หุ้นส่วนจำกัดปอยท์กราฟฟิก จำนวน 230 หน้า

- Arber, P.A., Tamayo, R. and Weiss, L.M. 1998. Parafin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. *Hum. Pathol.* 29(5): 498-504.
- Baker-Gabb, M., Hunt, G.B., France, M.P., 2003. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. *Aus. Vet. Journal.* 81: 732-8.
- Bettini, G., Morini, M. and Marcato, P.S. 2003. Gastrointestinal Spindle Cell Tumor of the Dog: Histological and Immunohistochem Study. *Journal of Comparative Pathology.* 129 (4): 283-293.
- Cameron L, et al. 2004. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. *J Vet Diagn Invest.* Vol. 16: 95-100.
- Dobson J.M. and Scase T. J. 2007. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. *Journal of Small Animal Practice.* Vol. 48: 424–431.
- Downing, S., Chien, M.B., Kaas, P.H., Moore, P.E., London, C.A. 2002. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. *Am. J. Vet. Res.* 63: 1718-1723.
- Fosmire, S.P., Dickerson, F.B., Scott, A.M., Bianco, S.R., Pettengil, M.J., Meylemans, H., Padilla, M., Frazer-Abel, A.A., Helfland, S.C. and Modiano, J.F. 2004. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. *Lab. Invest.* 84(5): 562-572.
- Gil da Costa, R.M., Matos E., Rema. A., Lopes. C., Pires, M.A., Gartner F. 2007. CD117 immunoexpression in canine mast cell tumor: correlation with pathological variables and proliferation markers. *B.M.C. Vet. Res.* 3:19.
- Govier, S.M., 2003. Principles of treatment for mast cell tumors. *Clinical Techniques in Small Animal Practice.* 18: 103–6.
- Kuipel, M., Webster, J.D., Kaneene, B., Miller, R., Yuzbasiyan-Gurkan,V. 2004. The Use of *KIT* and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors. *Vet. Pathol.* 41:371-377.

- Kubo, K., Katayama, K., Yonezama, K., Kotani, T., Ohashi, F., Matsuyama, S., Tsutsumi, C., Shimada, T., Sakuma, S. and Takamori, Y. 1998. Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor. *Journal of Veterinary Science.* 60 (12): 1335-1340.
- London, C.A., Kissnerberth, W.C., Galli, S.J., Geissler, E.N., Helfand, S.C. 1996. Expression of stem cell factor receptor (c-kit) by malignant mast cells from spontaneous canine mast cell tumours. *J. Comp .Pathol.* 113: 399-414.
- London, C.A., Galli, S.J., Yuuki, T., Hu, Z.Q., Helfand, S.C., Geissler, E.N. 1999. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene *c-kit*. *Exp. Hematol.* 27: 689-697.
- London, C.A., Hannah, A.L., Zadovoskaya, R., Chien, M.B., Kollias-Baker, C., Rosenberg, M., Downing, S., Post, G., Boucher, J., Shenoy, N., Mendel, D.B., McMahon, G. and Cherrington, J.M. 2003. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. *Clin. Cancer. Res.* 9: 2755-2768.
- London, C.A., Malpas, P.B., Wood-Follis, S.L., Boucher, J.F., Rusk, A.W., Rosenberg, M.P., Henry, C.J., Mitchener, K.L., Klein, M.K., Hintermeister, J.G., Bergman, P.J., Couto, G.C., Mauldin, G.N. and Michels, G.M. 2009. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. *Clin. Cancer. Res.* 15 (11): 3856-3865.
- London, C.A. 2009. Tyrosine kinase inhibitors in veterinary medicine. *Top. Companion. Anim. Med.* 24 (3): 106-112.
- Loplamlert, N, Kanjanachinto, C, Kultrailak, S., Wagnraitham, S., Ketpun, D., and Sailsuta, A. 2010. A comparative study on c-kit expression and standard histopathology on grading of canine cutaneous mast cell tumor, Proceedings the 36<sup>th</sup> International Conference on Veterinary Science 2010, Impact Challanger Hall, Kuang thong thani, Nonthaburi, Thailand 2-5 November 2010, p. 140
- Ma Y, et al. 1999. Clustering of activating mutations in c-kit's juxtamembrane coding region in canine mast cell neoplasms. *The journal of investigative dermatology.* Vol. 112(2): 165-170.

- Morini, M., Bettini, G., Preziosi, R. and Mandrioli, L. 2004. c-kit Gene product (CD 117) immunoreactivity I Canine and Feline Paraffin Sections (Brief report). *Journal of Histochemistry and Cytochemistry*. 52(5): 705-708.
- Owen, S.D. 1980. TNM classification of Tumor in Domestic Animals. World Health Organisation, Geneva.
- Patnaik A.K, Ehler W.J, MacEwen E.G. 1984. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. *Vet Pathol*. Vol. 21(5): 469-74.
- Prihirunkij K, Srisampan, S., and Bunnuang, U. 2007. Diagnosis of mast cell leukemia in a dog using MAPSS™ flow cytometry combined with toluidine blue. *Journal of the Thai Veterinary Medical Association Under the Royal Patronage*. Vol. 57(3): 64-72.
- Pryer K.N, Lee, L.B., Zadovaskaya, R., Yu, X., Sukbuntherng, J., Cherrington, J.M., and London, C.A. 2003. Proof of Target for SU11654: Inhibition of KIT phosphorylation in canine mast cell tumors. *Clini Cancer Res*. Vol. 9: 5729–5734.
- Reguera, M.J., Ferrer, L., and Rabanal, R.M., 2002. Evaluation of intron deletion in the *c-KIT* gene of canine mast cell tumors. *Am. J. Vet. Res.* 63:1257-1261.
- Riva, F., Brizzola, S., Stefanello, D., Crema, S and Turin, L. 2005. A study of mutation in the c-kit gene of 32 dogs with mastocytoma. *J. Vet. Diagn. Invest.* 17(4): 385-388.
- Rothwell, T.L., Howlett, C.R., Middleton, D.J., Griffiths, D.A., Duff, B.C. 1987. Skin neoplasms of dogs in Sydney. *Aus. Vet. Journal*. 64: 161–4.
- Simose, J.P. Schoning, P. and Butine, M. 1994. Prognosis of canine mast cell tumors: A comparison of three methods. *Vet. Pathol.* 31: 637-647.
- Thamm D. H. and Vail D.M. 2007. Mast cell tumors. In: Withrow and MacEwen's Small animal clinical oncology. Stephen Withrow and David M. Vail (ed.) St Louis, Missouri, US: Elsevier. 402-424.
- Turin, L., Acocella, F., Stefanello, D., Oseliero, A., Fondrini, D., Brizzola, S. and Riva, F. 2006. Expression of *c-kit* proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction. *J. Vet. Diagn. Invest.* 18: 343–349.
- Webster, J.D., Kiupel, M., Kaneene, J.B., Miller, R. and Yuzbasiyan-Gurkan, V. 2004. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. *Vet. Pathol.* 41: 371–377.

- Webster, J.D., Yuzbasiyan-Gurkan, V., Kaneene, J.B., Miller, R., Resau, J.H. and Kiupel, M. 2006. The role of *c-kit* in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. *Neoplasia.* 8 (2): 104-111.
- Webster, J.D., Yuzbasiyan-Gurkan, V., Miller, R.A., Kaneene, J.B. and Kiupel, M. 2007. Cellular proliferation in canine cutaneous mast cell tumors: Associations with *c-kit* and its role in prognostication. *Vet. Pathol.* 44: 298-308.
- Yancey, M.F., Merritt, D.A., Lesman, S.P., Boucher, J.f., and Micheals, G.M. 2009. Pharmacokinetic properties of toceranib phosphate (Palladia<sup>TM</sup>, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. *J. Vet. Pharmacol. Therap.* Vol. 33: 162–171.
- Zemke, D., Yamini, B., and Yuzbasiyan-Gurkan, V. 2001. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT. *J Vet Diagn Invest* 13: 341–345.
- Zemke, D., Yamini, B., and Yuzbasiyan-Gurkan, V. 2002. Mutations in the Juxtamembrane Domain of *c-kit* are associated with higher grade mast cell tumors in dogs. *Vet Pathol.* Vol. 39: 529–535.